A photo of Assem G. Ziady.

Assem G. Ziady, PhD


  • Associate Professor, UC Department of Pediatrics
  • Associate Professor, Case Western Reserve University

About

Biography

Dr. Ziady received his undergraduate education at Boston College in biochemistry in 1993. He completed his graduate studies on cell physiology and received his PhD degree in 1999 from Case Western Reserve University. Following his postdoctoral training at the Department of Pediatrics at Case Western Reserve University, he began a year-long externship at the Cleveland Clinic Proteomic facility in early 2002. In 2003, Dr. Ziady joined the faculty at the Case Western Reserve University Department of Pediatrics as assistant professor. In 2011, Dr. Ziady joined the faculty at the Emory University Department of Pediatrics as an associate professor and served as the associate director of Cystic Fibrosis Basic & Translational Research at Emory University.

In 2014, Dr. Ziady was recruited by the CF program at Cincinnati Children’s Hospital Medical Center, where he joined the faculty as associate professor of pediatrics within the UC College of Medicine in November. Dr. Ziady’s research has been supported by the State of Ohio, the Cystic Fibrosis Foundation, and the National Institutes of Health. His laboratory focuses on the differential regulation of Nrf2 signaling pathways in the inflammatory lung disease observed cystic fibrosis. Dr. Ziady's lab also has unique expertise in developing and characterizing DNA nanoparticles for nonviral gene delivery to the lung, liver, and brain. Finally, Dr. Ziady’s lab has expertise in proteomic analyses for biomarker discovery and the examination of systems biology of various tissues. He is an inventor on five patents (2 USA, 2 EU, and 1 international) pertaining to DNA nanoparticles, and one provisional patent pertaining to modulation of inflammatory signaling. In the past 15 years, he has authored 33 manuscripts and book chapters, has an h-index of 19, and has been invited to present 42 talks on his work at national and international conferences and institutions.

Publications

Selected

Clinically-approved CFTR modulators rescue Nrf2 dysfunction in cystic fibrosis airway epithelia. Borcherding, DC; Siefert, ME; Lin, S; Brewington, J; Sadek, H; Clancy, JP; Plafker, SM; Ziady, AG. Journal of Clinical Investigation. 2019; 129:3448-3463.

Selected

Near infrared light-triggered drug generation and release from gold nanoparticle carriers for photodynamic therapy. Cheng, Y; Doane, TL; Chuang, C; Ziady, A; Burda, C. Small. 2014; 10:1799-1804.

Selected

Interaction with CREB binding protein modulates the activities of Nrf2 and NF-κB in cystic fibrosis airway epithelial cells. Ziady, AG; Sokolow, A; Shank, S; Corey, D; Myers, R; Plafker, S; Kelley, TJ. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2012; 302:L1221-L1231.

Selected

Genetic variation and clinical heterogeneity in cystic fibrosis. Drumm, ML; Ziady, AG; Davis, PB. Annual Review of Pathology: Mechanisms of Disease. 2012; 7:267-282.

Selected

DNA nanoparticles: detection of long-term transgene activity in brain using bioluminescence imaging. Yurek, DM; Fletcher, AM; McShane, M; Kowalczyk, TH; Padegimas, L; Weatherspoon, MR; Kaytor, MD; Cooper, MJ; Ziady, AG. Molecular Imaging. 2011; 10:327-339.

Selected
Selected

Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Konstan, MW; Davis, PB; Wagener, JS; Hilliard, KA; Stern, RC; Milgram, LJ H; Kowalczyk, TH; Hyatt, SL; Fink, TL; Gedeon, CR; et al. Human Gene Therapy. 2004; 15:1255-1269.

Selected

Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Ziady, AG; Gedeon, CR; Miller, T; Quan, W; Payne, JM; Hyatt, SL; Fink, TL; Muhammad, O; Oette, S; Kowalczyk, T; et al. Molecular Therapy. 2003; 8:936-947.